ADVA
20.5.2020 09:02:09 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that it has upgraded its complete portfolio of Oscilloquartz PTP grandmaster clocks, enabling power utilities to smoothly transition to packet network synchronization. The enhanced technology will empower electricity providers to evolve their infrastructure into smart grids based on Precision Time Protocol (PTP) power profiles, while at the same time supporting all legacy timing signals. Updates to ADVA’s Oscilloquartz pluggable solution, its compact small cell device, its mid-size PTP grandmasters and its fully redundant core timing technology ensure ultra-precise timing throughout the utility network. What’s more, the technology removes the risk of relying purely on satellite-based time sources through continuous monitoring, jamming and spoofing detection and AI-assisted analytics.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200520005048/en/
“Our upgraded technology makes it simple to modernize utility infrastructure. Now, power network operators can achieve the accurate and stable synchronization needed to develop smart grid power networks built on packet-based solutions, while also maintaining legacy timing,” said Gil Biran, general manager, Oscilloquartz, ADVA. “Our technology provides a clear and cost-efficient path to robust and future-proof utility network synchronization. Its PTP timing delivery complements and replaces legacy protocols, enabling the accurate and resilient timing needed for emerging intelligent applications. Along with our multi-constellation GNSS receivers, PTP backup is also essential for protecting critical power networks. This ensures efficient operations and the best protection from malicious attacks.”
ADVA’s entire range of Oscilloquartz grandmaster clocks has been upgraded to meet the latest PTP profiles for time, frequency and phase synchronization in power utility networks. This includes the OSA 5401 small form-factor pluggable, the OSA 5405 for indoor and outdoor substation deployments, the OSA 5420 Series, and the highly scalable OSA 5430 and 5440 with 10Gbit/s interfaces and fully redundant hardware. The technologies enable an easy migration to an Ethernet-based timing network with support for PTP, Network Time Protocol (NTP) and SyncE, as well as IRIG-B, PPS and BITS legacy interfaces. PTP-based backup combined with multi-band GNSS receivers and advanced monitoring capabilities ensure that the upgraded solutions provide highly reliable delivery of precise timing information even during long GNSS outages. And, to create an ePRTC solution, ADVA’s Oscilloquartz cesium clocks can also be combined with the OSA 5420, 5430 or 5440. This delivers extended holdover of up to 70 nanoseconds for 14 days, even when GNSS signals are unavailable.
”By optimizing our synchronization technology, we’re enabling power utilities to achieve the stringent levels of precision necessary for synchronization from the substation to the core of the smart grid network. Our comprehensive portfolio empowers utilities to complement and then replace their legacy timing protocols with PTP. What’s more, our continually evolving software supports the broadest range of interfaces and profiles, ensuring a solution ready to grow with future needs,” commented Nir Laufer, senior director, product line management, Oscilloquartz, ADVA. ”IRIG-B and NTP have served the utility industry well. But the future is all about PTP power profiles delivering new levels of precision and reliability to substations with or without GNSS. This upgrade ensures operators can rely on extremely accurate frequency, phase and time services without the threat of outages caused by jamming and spoofing.”
Watch this video for more information: https://youtu.be/iHA_TI32T6A .
Further details are also provided in these slides: https://adva.li/power-utilities-slides .
A supporting solution sheet is available here: https://adva.li/smart-grids-solution-sheet .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we're creating new opportunities for tomorrow's networks. For more information, please visit us at www.oscilloquartz.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200520005048/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altasciences Supports 4B Healthcare in Advancing Steroid Nasal Irrigation Rinse to Clinical Trials24.9.2026 14:40:00 CEST | Press release
Altasciences is proud to announce that recent formulation work supporting 4B Healthcare Inc. (“4B”) has helped advance its RhineX nasal irrigation rinse therapy into clinical investigation. Following several months of formulation development, R&D manufacturing, stability testing, and quality assurance support at Altasciences’ CDMO facility in Harleysville, PA, the Tennessee-based pharmaceutical company has received FDA clearance to proceed with clinical testing of RhineX under its IND. First subject dosing is planned for October 2026, approximately seven months after formulation development began. "The concept for RhineX grew out of a problem I have seen in my own ENT practice for years—the need for a better treatment option for allergic rhinitis when conventional medical therapy is not enough,” said Brannon Mangus, MD, Co-Founder and CEO of 4B. “We founded 4B Healthcare to take that physician insight and turn it into a pharmaceutical product that could meaningfully change how these pa
ParaScript Acquired by Stakk to Create a Global Digital Trust Platform Focused on Combating Fraud24.9.2026 14:30:00 CEST | Press release
ParaScript’s AI-powered document intelligence technology integrates with Stakk’s SaaS platform to provide regulated organizations with a stronger defense against AI-driven digital identity fraud.Complementary technologies establish digital trust by continuously assessing identity, documents, behavior and context, making explainable decisions in milliseconds.Combined businesses serve more than 300 enterprise customers and processes more than 110 billion digital interactions annually across the U.S., Europe, the Middle East and Australia. ParaScript, an Al-powered document processing company, today announced that Stakk Limited (ASX: SKK) (“Stakk”), a company publicly traded on the Australian Stock Exchange (ASX), has successfully completed its US$63 million (A$88.7 million) acquisition of ParaScript, LLC and ParaScript Management, Inc. (“ParaScript”), creating a scaled and profitable AI-native digital trust platform. Stakk acquired ParaScript for its industry-leading AI-powered document
SLB Awarded Four Multi-Year Integrated Well Construction Contracts by Aramco24.9.2026 14:04:00 CEST | Press release
Awards expand deployment of SLB's integrated well construction model across Saudi Arabia’s oil and gas reservoirs Global energy technology company SLB (NYSE: SLB) today announced it has been awarded four integrated well construction contracts by Aramco to support oil and gas development across the Kingdom of Saudi Arabia. Under the contracts, SLB will manage end-to-end well construction services, delivering more than 450 wells in the three-year term, with an optional extension of up to two years. "Delivering hundreds of wells across a multi-year program and in multiple operating environments requires an integrated model that connects planning, execution, and digital workflows to set new industry performance benchmarks,” said Steve Gassen, executive vice president of Geographies for SLB. “Awarding SLB these advanced well construction programs at scale reflects Aramco’s confidence in our integrated model and capabilities." SLB's integrated well construction model brings together every as
Sahajanand Medical Technologies Receives EU MDR Certification for Supraflex Cruz and Product Family, Reinforcing Global Compliance and Patient Safety24.9.2026 14:03:00 CEST | Press release
Sahajanand Medical Technologies Limited (SMT), a leading global manufacturer of cardiovascular medical devices, today announced that it has received certification under the European Union Medical Device Regulation (EU MDR 2017/745) for Supraflex Cruz and its product family. SMT is a leading player in India’s drug-eluting stent market and ranks among the top five companies in key European markets, including Germany, Spain and Poland. The certification follows the conformity assessment process established under EU MDR 2017/745 including assessment of SMT’s technical documentation, clinical evaluation and quality management system. Together with SMT’s existing ISO 13485 quality management system and MDSAP certifications, the EU MDR certification confirms that Supraflex Cruz has successfully undergone assessment against the EU MDR’s stringent requirements for safety, performance and clinical evidence. Supraflex Cruz is a sirolimus-eluting coronary stent system designed to improve luminal d
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)24.9.2026 13:00:00 CEST | Press release
-- Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 development of 60 mg once daily remlifanserin in ADP, with demonstrated evidence of dose effect-- Narrowly missed primary endpoint of SAPS H+D (p=0.0603) with significance (nominal) on key secondary endpoint of CGI-S-ADP (p=0.0077)-- Favorable safety and tolerability profile across both doses-- Detailed results to be presented at upcoming Clinical Trials on Alzheimer's Disease (CTAD) conference in November-- Conference call and webcast to be held today at 8:00 a.m. Eastern Time Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). For the primary endpoint of change from baseline in the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom